2026 Q1 Portfolio Activity
In 2026 Q1, DAFNA Capital Management LLC maintained a portfolio of 87 distinct positions. The most significant new addition was FULCRUM THERAPEUTICS INC, now representing 0.36% of the total fund value. They heavily accumulated shares in NEKTAR THERAPEUTICS, increasing the position by 120.2%. The fund also reduced its exposure to CYTOKINETICS INC by 41.4%.
Position History
hover any row below to update
Loading…
Total Positions
87
Quarter
2026 Q1
Top Holding
RVMD (12.8%)
Top 10 Concentration
52.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 87
DAFNA Capital Management LLC Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 12.85% | 11.18% |
#1
Prev: #1
|
6.5 |
—
|
-23,836 | -3.9% |
P
S
|
580,678 | $56,470,936 |
$30.97
+394.2%
|
2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
XBI
SPDR S&P BIOTEC...
|
ETF | 9.25% | 9.53% |
#2
Prev: #2
|
5.7 |
—
|
-18,000 | -5.3% |
P
S
|
318,505 | $40,682,644 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
STXS
STEREOTAXIS INC
|
Healthcare | 5.73% | 7.31% |
#3
Prev: #3
|
4.3 |
—
|
no change | no change |
P
S
|
13,680,554 | $25,172,219 | 2012 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DAWN
DAY ONE BIOPHAR...
|
Healthcare | 4.77% | 2.16% |
#4
9
Prev: #13
|
2.9 |
—
|
-20,700 | -2.1% |
P
S
|
978,463 | $20,978,247 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ATRC
ATRICURE INC
|
Healthcare | 3.88% | 5.49% |
#5
1
Prev: #4
|
3.1 |
—
|
no change | no change |
P
S
|
597,431 | $17,044,706 | 2012 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IDYA
IDEAYA BIOSCIEN...
|
Healthcare | 3.61% | 4.07% |
#6
Prev: #6
|
1.9 |
—
|
-30,000 | -5.9% |
P
S
|
476,740 | $15,884,977 | 2020 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 3.32% | 3.00% |
#7
1
Prev: #8
|
1.8 |
—
|
-37,167 | -12.9% |
P
S
|
250,772 | $14,582,392 | 2015 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 3.26% | 5.48% |
#8
3
Prev: #5
|
1.3 |
—
|
-153,500 | -41.4% |
P
S
|
217,497 | $14,335,227 | 2015 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 3.04% | 1.30% |
#9
10
Prev: #19
|
4.2 |
—
|
1,607,836 | 198.2% |
P
S
|
2,418,882 | $13,376,417 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NKTR
NEKTAR THERAPEU...
|
Healthcare | 2.70% | 0.74% |
#10
26
Prev: #36
|
4.1 |
—
|
90,180 | 120.2% |
P
S
|
165,178 | $11,884,557 | 2009 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IBB
ISHARES NASDAQ ...
|
ETF | 2.39% | 2.67% |
#11
2
Prev: #9
|
1.5 |
—
|
-6,000 | -8.8% |
P
S
|
62,095 | $10,484,741 | 2006 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RCUS
ARCUS BIOSCIENC...
|
Healthcare | 2.18% | 2.39% |
#12
1
Prev: #11
|
1.4 |
—
|
12,500 | 2.9% |
P
S
|
443,829 | $9,586,706 | 2018 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 2.12% | 2.33% |
#13
1
Prev: #12
|
1.8 |
—
|
no change | no change |
P
S
|
70,615 | $9,302,820 | 2008 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LRMR
LARIMAR THERAPE...
|
Healthcare | 2.08% | 0.83% |
#14
18
Prev: #32
|
3.8 |
—
|
1,090,000 | 116.1% |
P
S
|
2,029,164 | $9,131,238 | 2020 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 1.91% | 1.02% |
#15
9
Prev: #24
|
3.8 |
—
|
160,150 | 61.2% |
P
S
|
421,733 | $8,388,269 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AXGN
AXOGEN INC
|
Healthcare | 1.88% | 3.63% |
#16
9
Prev: #7
|
0.8 |
—
|
-226,866 | -47.6% |
P
S
|
249,960 | $8,281,175 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 1.63% | 2.51% |
#17
7
Prev: #10
|
1.2 |
—
|
-109,500 | -11.5% |
P
S
|
845,735 | $7,154,918 | 2018 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TNDM
TANDEM DIABETES...
|
Healthcare | 1.55% | 1.81% |
#18
4
Prev: #14
|
1.6 |
—
|
no change | no change |
P
S
|
355,208 | $6,809,337 | 2015 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DNLI
DENALI THERAPEU...
|
Healthcare | 1.39% | 1.22% |
#19
3
Prev: #22
|
1.6 |
—
|
no change | no change |
P
S
|
318,500 | $6,115,200 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
ASCENDIS PHARMA...
|
|
Bond/Debt | 1.35% | 1.27% |
#20
1
Prev: #21
|
1.5 |
—
|
no change | no change |
P
S
|
4,000,000 | $5,916,500 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
IPSC
CENTURY THERAPE...
|
Healthcare | 1.25% | 0.65% |
#21
17
Prev: #38
|
1.0 |
—
|
-359,233 | -12.9% |
P
S
|
2,434,353 | $5,501,638 | 2021 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DXCM
DEXCOM INC
|
Healthcare | 1.23% | 1.36% |
#22
6
Prev: #16
|
1.0 |
—
|
-2,000 | -2.3% |
P
S
|
86,279 | $5,418,321 | 2012 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KALV
KALVISTA PHARMA...
|
Healthcare | 1.22% | 1.34% |
#23
5
Prev: #18
|
0.5 |
—
|
-89,400 | -25.1% |
P
S
|
267,402 | $5,382,802 | 2018 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 1.21% | 1.40% |
#24
9
Prev: #15
|
1.0 |
—
|
-5,000 | -17.7% |
P
S
|
23,177 | $5,301,275 | 2015 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 1.19% | 1.21% |
#25
2
Prev: #23
|
2.5 |
—
|
10,200 | 6.2% |
P
S
|
175,465 | $5,237,630 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
INGN
INOGEN INC
|
Healthcare | 1.19% | 1.29% |
#26
6
Prev: #20
|
1.0 |
—
|
18,108 | 2.2% |
P
S
|
845,179 | $5,223,206 | 2019 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 1.16% | 1.36% |
#27
10
Prev: #17
|
0.5 |
—
|
-60,500 | -21.8% |
P
S
|
217,355 | $5,077,413 | 2020 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 1.12% | 0.85% |
#28
3
Prev: #31
|
2.4 |
—
|
9,234 | 7.1% |
P
S
|
139,482 | $4,932,084 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
STOK
STOKE THERAPEUT...
|
Healthcare | 0.97% | 0.80% |
#29
4
Prev: #33
|
2.9 |
—
|
22,000 | 20.2% |
P
S
|
130,875 | $4,261,290 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 0.93% | 0.76% |
#30
5
Prev: #35
|
0.9 |
—
|
11,993 | 2.9% |
P
S
|
430,248 | $4,095,961 | 2014 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GLPG
GALAPAGOS NV
|
Healthcare | 0.89% | 0.99% |
#31
6
Prev: #25
|
1.4 |
—
|
no change | no change |
P
S
|
130,175 | $3,905,250 | 2015 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 0.85% | 0.89% |
#32
4
Prev: #28
|
1.3 |
—
|
no change | no change |
P
S
|
150,524 | $3,739,016 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 0.80% | 0.92% |
#33
6
Prev: #27
|
0.3 |
—
|
-47,500 | -29.7% |
P
S
|
112,236 | $3,535,434 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MPLT
MAPLIGHT THERAP...
|
Healthcare | 0.79% | 0.59% |
#34
7
Prev: #41
|
2.3 |
—
|
27,242 | 18.9% |
P
S
|
171,006 | $3,476,552 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALLO
ALLOGENE THERAP...
|
Healthcare | 0.76% | 0.44% |
#35
16
Prev: #51
|
0.8 |
—
|
-10,000 | -0.7% |
P
S
|
1,370,118 | $3,343,088 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PRCT
PROCEPT BIOROBO...
|
Healthcare | 0.68% | 0.88% |
#36
7
Prev: #29
|
1.3 |
—
|
no change | no change |
P
S
|
120,000 | $3,001,200 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALGN
ALIGN TECHNOLOG...
|
Healthcare | 0.58% | 0.58% |
#37
5
Prev: #42
|
0.7 |
—
|
-1,000 | -6.2% |
P
S
|
15,000 | $2,571,450 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PRQR
PROQR THERAPEUT...
|
Healthcare | 0.58% | 0.74% |
#38
1
Prev: #37
|
1.2 |
—
|
no change | no change |
P
S
|
1,567,561 | $2,539,449 | 2017 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CYBN
CYBIN INC
|
Unknown | 0.54% | 0.86% |
#39
9
Prev: #30
|
2.2 |
—
|
43,343 | 9.5% |
P
S
|
498,361 | $2,392,133 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RAPP
RAPPORT THERAPE...
|
Healthcare | 0.53% | 0.53% |
#40
5
Prev: #45
|
1.2 |
—
|
no change | no change |
P
S
|
75,000 | $2,346,750 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PODD
INSULET CORP
|
Healthcare | 0.52% | 0.45% |
#41
9
Prev: #50
|
3.2 |
—
|
4,000 | 58.2% |
P
S
|
10,870 | $2,280,961 | 2008 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 0.51% | 0.60% |
#42
2
Prev: #40
|
2.7 |
—
|
9,500 | 25.7% |
P
S
|
46,500 | $2,241,300 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IMTX
IMMATICS NV
|
Healthcare | 0.51% | 0.64% |
#43
4
Prev: #39
|
0.7 |
—
|
-35,278 | -13.5% |
P
S
|
225,860 | $2,222,462 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 0.49% | 0.43% |
#44
8
Prev: #52
|
1.2 |
—
|
no change | no change |
P
S
|
68,518 | $2,173,391 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 0.49% | 0.79% |
#45
11
Prev: #34
|
2.2 |
—
|
36,200 | 10.6% |
P
S
|
377,059 | $2,164,319 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALEC
ALECTOR INC
|
Healthcare | 0.44% | 0.33% |
#46
10
Prev: #56
|
1.2 |
—
|
no change | no change |
P
S
|
908,351 | $1,952,955 | 2019 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VKTX
VIKING THERAPEU...
|
Healthcare | 0.44% | 0.49% |
#47
2
Prev: #49
|
1.2 |
—
|
no change | no change |
P
S
|
59,516 | $1,936,651 | 2018 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KURA
KURA ONCOLOGY I...
|
Healthcare | 0.44% | 0.57% |
#48
5
Prev: #43
|
1.2 |
—
|
no change | no change |
P
S
|
235,868 | $1,917,607 | 2017 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PROF
PROFOUND MEDICA...
|
Healthcare | 0.39% | 0.52% |
#49
3
Prev: #46
|
0.7 |
—
|
-22,705 | -7.9% |
P
S
|
263,005 | $1,704,272 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
FULC
FULCRUM THERAPE...
|
Healthcare | 0.36% | — |
#50
Prev: #—
|
3.6 |
—
|
205,000 | — |
NEW
|
205,000 | $1,572,350 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-50 of 87 holdings